Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe
- 29 August 2017
- journal article
- research article
- Published by IOS Press in Journal of Alzheimer's Disease
- Vol. 60 (1), 201-210
- https://doi.org/10.3233/jad-170502
Abstract
Background: BIOMARKAPD seeks to diminish the barriers associated with the clinical use of cerebrospinal fluid (CSF) biomarker analysis by reducing variation in CSF laboratory methodologies and generating consensus recommendations on their clinical interpretation and application for dementia diagnosis. Objective: To examine the disparity in practitioner attitudes and clinical practice relating to the use of CSF biomarkers for dementia diagnosis across Europe. Methods: Clinical dementia experts were surveyed on the prevalence of national consensus guidelines and analytical reimbursement across Europe, their biomarker platform preferences, lumbar puncture methodologies and application of reference values and cut-offs for CSF analysis. Results: 74% of respondents (total n = 51) use CSF biomarkers in clinical practice and 69% perform lumbar punctures on an outpatient basis. Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%). 82% state they are sufficiently informed about CSF biomarkers yet 61% report a lack of national consensus guidelines on their use for dementia diagnosis. 48% of countries represented do not reimburse clinical CSF analysis costs. 43% report using normal reference ranges derived from publications. Conclusion: Variations in attitude and practice relating to CSF biomarkers, widely recognised as barriers to their clinical acceptance, remain evident within and between countries across Europe, even in expert centres. These shortcomings must be addressed by developing consensus guidelines on CSF-related methodologies and their clinical application, to further their use for the diagnostic evaluation of dementia.This publication has 38 references indexed in Scilit:
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology and Experimental Neurology, 2012
- Age and diagnostic performance of Alzheimer disease CSF biomarkersNeurology, 2012
- Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent LiteratureJournal of Nuclear Medicine, 2011
- Cerebrospinal fluid biomarkers of Alzheimer’s diseaseBiomarkers in Medicine, 2010
- The clinical use of structural MRI in Alzheimer diseaseNature Reviews Neurology, 2010
- Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer’s Disease in Clinical Practice: An Illustration with 3 Case ReportsCase Reports in Neurology, 2010
- Use of cerebrospinal fluid biomarkers in diagnosis of dementia across EuropeEuropean Journal of Neurology, 2009
- Biomarkers of Alzheimer's diseaseNeurobiology of Disease, 2009
- Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular DementiaThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2006
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984